Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2010 (2010), Article ID 750904, 6 pages
http://dx.doi.org/10.1155/2010/750904
Review Article

Toll-Like Receptor 3 in Liver Diseases

Shi Yin1,2 and Bin Gao1

1Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, 5625 Fishers Lane, MD 20892, USA
2Department of Geriatrics, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, China

Received 27 April 2010; Accepted 14 July 2010

Academic Editor: Ekihiro Seki

Copyright © 2010 Shi Yin and Bin Gao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Trivedi and E. L. Greidlinger, “Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity,” Therapy, vol. 6, no. 3, pp. 433–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. F. Kenny and L. A. J. O'Neill, “Signalling adaptors used by Toll-like receptors: an update,” Cytokine, vol. 43, no. 3, pp. 342–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Vercammen, J. Staal, and R. Beyaert, “Sensing of viral infection and activation of innate immunity by toll-like receptor 3,” Clinical Microbiology Reviews, vol. 21, no. 1, pp. 13–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Schröder and A. G. Bowie, “TLR3 in antiviral immunity: key player or bystander?” Trends in Immunology, vol. 26, no. 9, pp. 462–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Seki and D. A. Brenner, “Toll-like receptors and adaptor molecules in liver disease: update,” Hepatology, vol. 48, no. 1, pp. 322–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Szabo, A. Dolganiuc, and P. Mandrekar, “Pattern recognition receptors: a contemporary view on liver diseases,” Hepatology, vol. 44, no. 2, pp. 287–298, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Mencin, J. Kluwe, and R. F. Schwabe, “Toll-like receptors as targets in chronic liver diseases,” Gut, vol. 58, no. 5, pp. 704–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Khvalevsky, L. Rivkin, J. Rachmilewitz, E. Galun, and H. Giladi, “TLR3 signaling in a hepatoma cell line is skewed towards apoptosis,” Journal of Cellular Biochemistry, vol. 100, no. 5, pp. 1301–1312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Li, Z. Chen, N. Kato, M. Gale Jr., and S. M. Lemon, “Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-β production in hepatocytes,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 16739–16747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Wang, Y. Liang, S. Devaraj, J. Wang, S. M. Lemon, and K. Li, “Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells,” Journal of Virology, vol. 83, no. 19, pp. 9824–9834, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Wang, M. Trippler, R. Pei et al., “Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication,” Journal of Hepatology, vol. 51, no. 6, pp. 1037–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Xiao, P. Zhao, D. Rodriguez-Pinto et al., “Inflammatory regulation by TLR3 in acute hepatitis,” Journal of Immunology, vol. 183, no. 6, pp. 3712–3719, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Nakamura, K. Funami, A. Komori et al., “Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers,” Hepatology International, vol. 2, no. 2, pp. 222–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Takii, M. Nakamura, M. Ito et al., “Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis,” Laboratory Investigation, vol. 85, no. 7, pp. 908–920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Gardner, Q. Chen, Y. Jin, and M. Ajuber, “Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha14 invariant natural killer T cells to negatively regulate gamma/delta T cells,” American Journal of Pathology, vol. 176, no. 5, pp. 1779–1789, 2010. View at Google Scholar
  16. R. H. Wiltrout, B. J. Mathieson, and J. E. Talmadge, “Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver,” Journal of Experimental Medicine, vol. 160, no. 5, pp. 1431–1449, 1984. View at Google Scholar · View at Scopus
  17. R. H. Wiltrout, A. M. Pilaro, M. E. Gruys et al., “Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow,” Journal of Immunology, vol. 143, no. 1, pp. 372–378, 1989. View at Google Scholar · View at Scopus
  18. J. Wang, J. Xu, W. Zhang, H. Wei, and Z. Tian, “TLR3 ligand-induced accumulation of activated splenic natural killer cells into liver,” Cellular Molecular of Immunology, vol. 2, no. 6, pp. 449–453, 2005. View at Google Scholar · View at Scopus
  19. M. Zhang, Y. Han, C. Han et al., “The beta2 integrin CD11b attenuates polyinosinic:polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions,” Hepatology, vol. 50, no. 5, pp. 1606–1616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Dong, H. Wei, R. Sun, Z. Hu, B. Gao, and Z. Tian, “Involvement of natural killer cells in PolyI:C-induced liver injury,” Journal of Hepatology, vol. 41, no. 6, pp. 966–973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Hou, R. Zhou, H. Wei, R. Sun, and Z. Tian, “NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis,” Hepatology, vol. 49, no. 3, pp. 940–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Chen, R. Sun, W. Jiang, H. Wei, and Z. Tian, “Liver-specific HBsAg transgenic mice are over-sensitive to Poly(I:C)-induced liver injury in NK cell- and IFN-γ-dependent manner,” Journal of Hepatology, vol. 47, no. 2, pp. 183–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Chen, H. Wei, R. Sun, Z. Dong, J. Zhang, and Z. Tian, “Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells,” Hepatology, vol. 46, no. 3, pp. 706–715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Jiang, R. Sun, H. Wei, and Z. Tian, “Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17077–17082, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. K. Michalopoulos, “Liver regeneration,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 286–300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Seki, H. Tsutsui, Y. Iimuro et al., “Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration,” Hepatology, vol. 41, no. 3, pp. 443–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. S. Campbell, K. J. Riehle, J. T. Brooling, R. L. Bauer, C. Mitchell, and N. Fausto, “Proinflammatory cytokine production in liver regeneration is Myd88-dependent, but independent of Cd14, Tlr2, and Tlr4,” Journal of Immunology, vol. 176, no. 4, pp. 2522–2528, 2006. View at Google Scholar · View at Scopus
  29. E. Zorde-Khvalevsky, R. Abramovitch, H. Barash et al., “Toll-like receptor 3 signaling attenuates liver regeneration,” Hepatology, vol. 50, no. 1, pp. 198–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Shen, S.-S. Zheng, O. Park, H. Wang, Z. Sun, and B. Gao, “Activation of innate immunity (NK/IFN-γ) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation,” American Journal of Physiology, vol. 294, no. 4, pp. G1070–G1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Sun and B. Gao, “Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-γ),” Gastroenterology, vol. 127, no. 5, pp. 1525–1539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Sun, O. Park, N. Horiguchi et al., “STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice,” Hepatology, vol. 44, no. 4, pp. 955–966, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Bataller and D. A. Brenner, “Liver fibrosis,” Journal of Clinical Investigation, vol. 115, no. 4, pp. 209–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. Friedman, “Mechanisms of Hepatic Fibrogenesis,” Gastroenterology, vol. 134, no. 6, pp. 1655–1669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Seki, S. De Minicis, C. H. Österreicher et al., “TLR4 enhances TGF-β signaling and hepatic fibrosis,” Nature Medicine, vol. 13, no. 11, pp. 1324–1332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Radaeva, R. Sun, B. Jaruga, V. T. Nguyen, Z. Tian, and B. Gao, “Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners,” Gastroenterology, vol. 130, no. 2, pp. 435–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. W.-I. Jeong, O. Park, S. Radaeva, and B. Gao, “STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity,” Hepatology, vol. 44, no. 6, pp. 1441–1451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Krizhanovsky, M. Yon, R. A. Dickins et al., “Senescence of activated stellate cells limits liver fibrosis,” Cell, vol. 134, no. 4, pp. 657–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Mallat, A.-M. Preaux, S. Blazejewski, J. Rosenbaum, D. Dhumeaux, and P. Mavier, “Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture,” Hepatology, vol. 21, no. 4, pp. 1003–1010, 1995. View at Google Scholar · View at Scopus
  40. H.-N. Pan, R. Sun, B. Jaruga, F. Hong, W.-H. Kim, and B. Gao, “Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis,” Alcoholism: Clinical and Experimental Research, vol. 30, no. 9, pp. 1615–1623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Jeong, O. Park, and B. Gao, “Abrogation of the antifibrotic effects of natural killer cells/interferon-γ contributes to acohol acceleration of liver fibrosis,” Gastroenterology, vol. 134, no. 1, pp. 248–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Hébert and S. B. Pruett, “Ethanol suppresses polyinosinic:polycytidylic acid-induced activation of natural killer cells primarily by acting on natural killer cells, not through effects on other cell types,” Alcohol, vol. 28, no. 2, pp. 75–81, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. S. D. Collier and S. B. Pruett, “Mechanisms of suppression of poly I:C-induced activation of NK cells by ethanol,” Alcohol, vol. 21, no. 1, pp. 87–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Wei, H. Wei, H. Wang, Z. Tian, and R. Sun, “Activation of natural killer cells inhibits liver regeneration in toxin-induced liver injury model in mice via a tumor necrosis factor-alpha-dependent mechanism,” American Journal of Physiology, vol. 299, no. 1, pp. G275–G282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari, “Toll-like receptor signaling inhibits hepatitis B virus replication in vivo,” Journal of Virology, vol. 79, no. 11, pp. 7269–7272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Wu, M. Lu, Z. Meng et al., “Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice,” Hepatology, vol. 46, no. 6, pp. 1769–1778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kanda, R. Steele, R. Ray, and R. B. Ray, “Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes,” Journal of Virology, vol. 81, no. 22, pp. 12375–12381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Perrin-Cocon, S. Agaugué, O. Diaz et al., “Th 1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically-infected by Hepatitis C virus,” PLoS One, vol. 3, no. 5, Article ID e2260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Duluc, F. Tan, M. Scotet et al., “PolyI:C plus IL-2 or IL-12 induce IFN-γ production by human NK cells via autocrine IFN-β,” European Journal of Immunology, vol. 39, no. 10, pp. 2877–2884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Li, Q. Li, Z. Qian, Y. Zhang, M. Chen, and G. Shi, “Impaired TLR3/IFN-β signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage,” Biochemical and Biophysical Research Communications, vol. 390, no. 3, pp. 630–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Li, E. Foy, J. C. Ferreon et al., “Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2992–2997, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Meylan, J. Curran, K. Hofmann et al., “Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus,” Nature, vol. 437, no. 7062, pp. 1167–1172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Foy, K. Li, R. Sumpter Jr. et al., “Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2986–2991, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Askar, R. Bregadze, J. Mertens et al., “TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C,” Journal of Medical Virology, vol. 81, no. 7, pp. 1204–1211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. K. S. Lang, P. Georgiev, M. Recher et al., “Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling,” Journal of Clinical Investigation, vol. 116, no. 9, pp. 2456–2463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Okada, F. Akbar, N. Horiike, and M. Onji, “Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration,” Liver International, vol. 25, no. 3, pp. 595–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Jiang, Z. Han, S. Chen et al., “Resistance to activation-induced cell death and elevated FLIPL expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model,” Clinical and Experimental Medicine, vol. 9, no. 4, pp. 269–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. T. K. Mao, Z.-X. Lian, C. Selmi et al., “Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis,” Hepatology, vol. 42, no. 4, pp. 802–808, 2005. View at Publisher · View at Google Scholar · View at Scopus